Drug Profile
PNU 170413
Alternative Names: PNU-170413Latest Information Update: 08 Sep 2006
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antipsychotics
- Mechanism of Action Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 08 Sep 2006 No development reported - Phase-I for Schizophrenia in USA (unspecified route)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 10 Jun 2002 Phase-I clinical trials in Schizophrenia in USA (unspecified route)